Approach to the patient: precision medicine-guided evaluation and treatment of acromegaly.
A biomarker-guided treatment strategy can lead to hormonal control in nearly 80% of patients with acromegaly, suggesting a shift towards precision medicine in managing this condition.
Where it sits
this study against the rest of the pasireotide corpusSummary and findings
This paper discusses the evaluation and treatment of acromegaly using precision medicine. It highlights the identification of distinct patient classes and the application of biomarker-guided treatment strategies. The study suggests that such strategies can lead to improved biochemical control and tumor volume reduction.
Abstract
Acromegaly is a heterogeneous disease in which delayed biochemical control remains common despite the availability of multiple therapeutic options. Traditional stepwise medical treatment algorithms often rely on the use of first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs with empirical escalation and trial-and-error approaches, prolonging patients' exposure to hormonal excess. Cluster analyses indicate that overall, 3 main classes of patients with acromegaly representing distinct biological phenotypes can be recognized: (1) young patients with invasive macroadenomas and frequent resistance to fgSRLs; (2) older patients with noninvasive tumors and SRL responsiveness in the majority of them; and (3) patients with intermediate features often requiring combination medical therapy in whom prediction of response is more challenging. From a practical perspective, biomarker-guided treatment selection based on T2-weighted magnetic resonance imaging signal intensity, the short acute octreotide test, and tumor immunohistochemistry, following the strategy validated in the ACROFAST study, is applicable in clinical practice. It allows prompt biochemical control and tumor volume reduction, a rationale leading to superior effectiveness performance than the classic sequencing therapy involving the universal utilization of fgSRLs as first option. In the era of integrative and participative medicine, such a protocol enables the early identification of most patients unlikely to respond to fgSRLs, thus supporting timely initiation of pegvisomant, pasireotide, or combination therapy, and the achievement of hormonal control in nearly 80% of patients. Conclusion Precision medicine has become a practical reality in acromegaly. A biomarker-guided strategy improves therapeutic efficiency and should be incorporated into contemporary clinical practice.
Background
Acromegaly is a complex disease characterized by excess growth hormone, leading to various health complications. Previous treatment approaches often relied on first-generation somatostatin receptor ligands, which may not be effective for all patients. This study is significant as it explores a precision medicine approach that could enhance treatment outcomes for patients with acromegaly.
Methods
The study employs cluster analyses to categorize patients into three distinct classes based on their tumor characteristics and treatment responses. It discusses the use of biomarkers, including T2-weighted MRI signal intensity and the short acute octreotide test, to guide treatment decisions. Specific details regarding sample size, dose, and duration were not provided in the abstract.
Results
The study indicates that a biomarker-guided treatment strategy can lead to hormonal control in nearly 80% of patients. It emphasizes the importance of identifying patients unlikely to respond to first-line therapies, enabling timely initiation of alternative treatments.
Interpretation
The findings suggest that a precision medicine approach may improve treatment efficacy compared to traditional methods. However, the clinical significance of achieving hormonal control in 80% of patients should be interpreted cautiously, as the abstract does not provide details on the robustness of these findings or potential confounding factors. Limitations such as small sample sizes or reliance on specific biomarkers may affect the generalizability of the results.
Key findings
- 80% of patients achieved hormonal control with biomarker-guided treatment.
- Three main classes of patients with distinct biological phenotypes were identified.
- The strategy validated in the ACROFAST study was mentioned as applicable in clinical practice.
Limitations
- Not reported in abstract.
- Details on sample size and duration were not provided.
- Potential confounding factors not discussed.